Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review
- 15 December 2010
- journal article
- review article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 118 (2), 123-135
- https://doi.org/10.1111/j.1471-0528.2010.02810.x
Abstract
BACKGROUND: Pregnant women are at increased risk from malaria. Resistance to all classes of antimalarials has affected the treatment and prevention of malaria in pregnancy. OBJECTIVES: To review the therapeutic efficacy of antimalarials used for treatment and intermittent preventive treatment (IPT) in pregnancy. SEARCH STRATEGY: We searched MEDLINE and the Cochrane Library between January 1998 and December 2009 for publications using the medical subject headings: efficacy, antimalarials, malaria, pregnancy, pharmacokinetics, treatment, IPT and placenta positive. In May 2010 we searched the register of clinical trials (http://clinicaltrials.gov/) and of WHO (http://apps.who.int/trialsearch/) using 'malaria', and 'pregnancy' and 'treatment'. SELECTION CRITERIA: We identified 233 abstracts, reviewed 83 full text articles and included 60 studies. DATA COLLECTION AND ANALYSIS: Two authors entered extracted data to an excel spreadsheet. MAIN RESULTS: Parasitological failure rates, placenta positivity rates (assessed by microscopy) or both were reported in 44% (21/48), 46% (22/48) and 10% (5/48) of articles, respectively. Most pharmacokinetic studies (9/12) suggested dose optimisation. In 23 treatment studies 17 different antimalarial drugs were delivered in 53 study arms; 43.4% (23/53) reported a failure rate of < 5%; 83.3% of sulphadoxine-pyrimethamine (SP) arms and 9% of artemisinin combination therapy (ACT) arms had failure rates ≥ 10%. Placenta-positive rates (mostly reported in the context of IPT in pregnancy) were > 10% in 68% (23/34) of SP trial arms and > 15% in all seven chloroquine arms. The ACT provided lower parasitological failure and gametocyte carriage rates. AUTHOR'S CONCLUSIONS: Drugs used in pregnancy should aim for 95% efficacy but many currently deployed regimens are associated with much lower cure ratesKeywords
This publication has 98 references indexed in Scilit:
- Pharmacokinetics of Chloroquine and Monodesethylchloroquine in PregnancyAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetic Properties of Azithromycin in PregnancyAntimicrobial Agents and Chemotherapy, 2010
- Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of UgandaMalaria Journal, 2009
- Placental malaria and low birth weight in pregnant women living in a rural area of Burkina Faso following the use of three preventive treatment regimensMalaria Journal, 2009
- Pharmacokinetic Properties of Sulfadoxine-Pyrimethamine in Pregnant WomenAntimicrobial Agents and Chemotherapy, 2009
- Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum MalariaAntimicrobial Agents and Chemotherapy, 2009
- Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatmentProceedings of the National Academy of Sciences, 2009
- Adverse Pregnancy Outcomes in an Area Where Multidrug‐ResistantPlasmodium vivaxandPlasmodium falciparumInfections Are EndemicClinical Infectious Diseases, 2008
- Effect of Sulfadoxine-Pyrimethamine Resistance on the Efficacy of Intermittent Preventive Therapy for Malaria Control During PregnancyJAMA, 2007
- Population Pharmacokinetic Assessment of a New Regimen of Mefloquine Used in Combination Treatment of Uncomplicated Falciparum MalariaAntimicrobial Agents and Chemotherapy, 2006